

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU SCIEN TECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*

樂普心泰醫療科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2291)

VOLUNTARY ANNOUNCEMENT

RF-Lance® DISPOSABLE RADIOFREQUENCY ATRIAL SEPTAL PUNCTURE NEEDLE PRODUCT OBTAINS MEDICAL DEVICE REGISTRATION CERTIFICATE

The board of directors (the “**Board**”) of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (the “**Company**”) is pleased to announce that Shanghai Shape Memory Alloy Co., Ltd.# (上海形狀記憶合金材料有限公司), a wholly-owned subsidiary of the Company, has obtained a medical device registration certificate granted by the National Medical Products Administration of the People’s Republic of China for the RF-Lance® Disposable Radiofrequency Atrial Septal Puncture Needle (“**RF-Lance® Disposable Radiofrequency Atrial Septal Puncture Needle**”).

The successful approval of RF-Lance® Disposable Radiofrequency Atrial Septal Puncture Needle not only enriches the Company’s product portfolio in the cardiac interventional access pipeline, but also lays a solid foundation for the Company’s continued development in this field. In the future, the Company will adhere to its original aspirations and be persistent in innovation-driven development. The Company will explore a wider range of medical applications focusing on the field of structural heart diseases. Through continuous technological innovation and product optimization, the Company will bring more advanced, more effective and safer solutions to better serve the clinics and benefit the patients.

The sales performance of RF-Lance® Disposable Radiofrequency Atrial Septal Puncture Needle will be subject to a number of factors including but not limited to clinical promotion, channel expansion, changes in competitive landscape and macro policies, in which there exist uncertainties of this product on the Company’s financial performance. Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*

樂普心泰醫療科技(上海)股份有限公司

Ms. Chen Juan

Chairman of the Board and Executive Director

Shanghai, the People’s Republic of China
July 25, 2024

As at the date of this announcement, the Board comprises Ms. Chen Juan as executive Director, Ms. Zhang Yuxin, Mr. Fu Shan and Mr. Zheng Guorui as non-executive Directors, and Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng, and Mr. Liu Daozhi as independent non-executive Directors.

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and it is registered under its Chinese name and under the English name “LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*

For identification purposes only.